Star Health and Allied Insurance Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Star Health and Allied Insurance (NSE: STARHEALTH) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 520 — against a 52-week high of Rs 775 and 1-year return of -28% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 5,500-5,900 Cr, with PAT expectations of Rs 120-160 Cr and margin projections of Combined Ratio 99-102%. This article covers the Star Health and Allied Insurance Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.

Star Health and Allied Insurance Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Why This Quarter Matters

Star Health and Allied Insurance enters Q4 FY26 with expectations of GWP 18-22% YoY growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -28%, this quarter’s results and FY27 guidance will be critical for determining whether the stock can sustain recovery momentum.

Star Health and Allied Insurance Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Screen Star Health and Allied Insurance fundamentals on Univest Screener.

5 Key Factors That Will Drive Star Health and Allied Insurance Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 5,500-5,900 Cr in Q4 FY26 revenue versus Rs 5,170 Cr in Q3. Q4 is seasonally important for the Insurance sector and the ability to convert the pipeline into recognised revenue will be the first performance test.

Margin Trajectory

Q4 FY26 margin expectations are Combined Ratio 99-102% versus Combined Ratio 103% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.

PAT Quality

Net profit is estimated at Rs 120-160 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue growth bands, margin targets, and capex plans. In the current global macro environment, credible FY27 guidance carries significant weight for the stock’s re-rating potential.

Dividend Declaration

Star Health and Allied Insurance is expected to consider a final dividend of Nil expected. The quantum signals management’s confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in Star Health and Allied Insurance Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Star Health and Allied Insurance, indirect impacts include FII outflows and earnings estimate cuts if global demand slows. India-US trade negotiations remain the most important macro catalyst.

Earnings Miss Risk

If Star Health and Allied Insurance’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 5,500-5,900 Cr and PAT versus Rs 120-160 Cr as the two primary watchpoints.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter in the current environment.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling would create headwinds for Star Health and Allied Insurance regardless of company-specific fundamentals.

Sector Regulatory Risk

The Insurance sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Star Health and Allied Insurance’s profitability beyond current consensus models.

Star Health and Allied Insurance Share Price and Analyst Ratings

Star Health and Allied Insurance is trading at Rs 520 as of early April 2026, against a 52-week high of Rs 775 and 52-week low of Rs 445. Market cap stands at Rs 30,500 Cr.

Download the Univest iOS App or Univest Android App to track Star Health and Allied Insurance live and receive real-time Q4 result alerts.

Conclusion

Star Health and Allied Insurance Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Insurance sector. Analysts project PAT of Rs 120-160 Cr and revenue of Rs 5,500-5,900 Cr. At a CMP of Rs 520 with analyst targets from Rs 650 to Rs 680, FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Star Health and Allied Insurance Q4 results 2026 date?

The Star Health and Allied Insurance Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.

What is the Star Health and Allied Insurance Q4 FY26 PAT estimate?

Analysts estimate Star Health and Allied Insurance Q4 FY26 PAT at Rs 120-160 Cr, based on revenue of Rs 5,500-5,900 Cr and margin of Combined Ratio 99-102%.

What is Star Health and Allied Insurance’s share price ahead of Q4 results?

Star Health and Allied Insurance is trading at Rs 520. The 52-week high is Rs 775 and low is Rs 445. The 1-year return is -28% and market cap is Rs 30,500 Cr.

Will Star Health and Allied Insurance declare a dividend in Q4 FY26?

Star Health and Allied Insurance is expected to consider a final dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Star Health and Allied Insurance?

MOFSL (Buy, Rs 680), YES Securities (Buy, Rs 660), JM Financial (Add, Rs 640), Emkay (Buy, Rs 650) have positive ratings heading into Q4 FY26.

What were Star Health and Allied Insurance Q3 FY26 results?

Star Health and Allied Insurance reported Q3 FY26 revenue of Rs 5,170 Cr and PAT of Rs 82 Cr, with margin at Combined Ratio 103%. These form the baseline for Q4 FY26 consensus estimates.

When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.

Is Star Health and Allied Insurance a good investment ahead of Q4 results?

This depends on your risk appetite and portfolio context. Star Health and Allied Insurance has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

UPL Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Zee Entertainment Enterprises Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Sun TV Network Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Sapphire Foods India Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Metro Brands Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook